Moreover, some clinical studies documented a better prognosis, in terms of progression-free survival (PFS) and OS, for Del19 compared to L858R-mutation NSCLC patients under treatment with EGFR-TKIs [25,26,27]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.